Halozyme Therapeutics Inc recorded an increase in cost of sales by 70.78 % year on year, relative to one quarter ago cost of sales fell by -0.08 % in Q2.
Halozyme Therapeutics Inc's Comment on Supply Chain
The company develops and supplies injection devices for Teva's generic Epinephrine Injection USP and teriparatide injection products, including a disposable pen injector and a multi-dose pen platform. Under a license, development, and supply agreement with Teva, the company receives upfront payments, milestones, and royalties. In 2020, Teva launched the generic Teriparatide Injection using the company's multi-dose pen platform. In November 2023, Teva announced FDA approval of the generic Forteo featuring the company's multi-dose auto-injector pen.
The company has a development agreement with Pfizer to create a combination drug-device rescue pen using the QuickShot auto-injector and an undisclosed Pfizer drug, with Pfizer providing intellectual property rights. Additionally, the company entered into a global development agreement initially with Idorsia Pharmaceuticals Ltd., later assigned to McDermott Laboratories Limited (an affiliate of Viatris), to develop a drug-device product containing selatogrel for acute myocardial infarction treatment. In December 2025, the company entered into a commercial license and supply agreement with Viatris to license and supply an auto-injector product for selatogrel treatment.
Halozyme Therapeutics Inc's Comment on Supply Chain
The company develops and supplies injection devices for Teva's generic Epinephrine Injection USP and teriparatide injection products, including a disposable pen injector and a multi-dose pen platform. Under a license, development, and supply agreement with Teva, the company receives upfront payments, milestones, and royalties. In 2020, Teva launched the generic Teriparatide Injection using the company's multi-dose pen platform. In November 2023, Teva announced FDA approval of the generic Forteo featuring the company's multi-dose auto-injector pen.
The company has a development agreement with Pfizer to create a combination drug-device rescue pen using the QuickShot auto-injector and an undisclosed Pfizer drug, with Pfizer providing intellectual property rights. Additionally, the company entered into a global development agreement initially with Idorsia Pharmaceuticals Ltd., later assigned to McDermott Laboratories Limited (an affiliate of Viatris), to develop a drug-device product containing selatogrel for acute myocardial infarction treatment. In December 2025, the company entered into a commercial license and supply agreement with Viatris to license and supply an auto-injector product for selatogrel treatment.
Sources:
Halozyme Therapeutics Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Halozyme Therapeutics Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
